Unveiling the Therapeutic Potential of Compounds Carrying Mono- and Bis-Thiazole Nuclei with Distinct Heterocyclic Analogues for Addressing Cancer Challenges.
T Saravanan, C Selvinthanuja, S Jubie, M K Kathiravan, R Thilagavathy, V Ravichandran, T Prabha
{"title":"Unveiling the Therapeutic Potential of Compounds Carrying Mono- and Bis-Thiazole Nuclei with Distinct Heterocyclic Analogues for Addressing Cancer Challenges.","authors":"T Saravanan, C Selvinthanuja, S Jubie, M K Kathiravan, R Thilagavathy, V Ravichandran, T Prabha","doi":"10.2174/0115680096375796250610065705","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The thiazole nucleus serves as a bioactive synthetic scaffold in drug design and discovery due to its diverse pharmacological activities. It was discovered that many types of thiazole derivatives, including those with one, two, or three substitutions, five- or six-membered heterocycles, fused rings, and thiazole-derived Schiff bases, hydrazinyl derivatives, amides, chalcones, and bis-thiazoles, can fight cancer. Thus, the structural diversity of thiazole nuclei makes it one of the significant areas of research in the pharmaceutical field.</p><p><strong>Objective: </strong>We would like to elaborate on the recent literature available on the antiproliferative property of molecules bearing 1,3-thiazole nuclei.</p><p><strong>Methods: </strong>This review summarises the anticancer potency of thiazole derivatives collected from recently available scientific literature. We extracted the information from online databases like PubMed, Scopus, and Web of Science using relevant keywords from 2016 to the present. We discuss the current state of thiazole derivatives and highlight the most promising compounds. We also describe how they work and what their half-maximum inhibitory concentration (IC50) is.</p><p><strong>Results: </strong>Based on our extensive literature review, we found that thiazole derivatives exhibit anticancer activity through their ability to induce apoptosis in cancer cells, mitochondrial membrane disruption by blocking signalling pathways such as Akt, NFkB, PI3K, and Src/Abl, and inhibition of proteins responsible for cell growth. Moreover, thiazole-protein interactions essential for cancer inhibition are predominantly regulated by hydrogen bonding, supported by the sulphur and nitrogen atoms in the thiazole molecule, which effectively interacts with the amino acids serine, tyrosine, and glutamine. π-π stacking and π-cation interactions involving aromatic amino acids such as tryptophan, tyrosine, and phenylalanine, along with hydrophobic effects and van der Waals forces, play a crucial role in thiazole-protein interactions. These interactions dictate binding affinity and efficacy, measured through thermodynamic characteristics such as Binding Constant (Kb), Dissociation Constant (Kd), and Gibbs free energy (ΔG). Comprehending these features is essential for the development of effective thiazole-based anticancer pharmaceuticals.</p><p><strong>Conclusion: </strong>This cumulative information is enough to give new ideas for the rational drug design of thiazole-based derivatives and could be pursued as a promising lead in the future for the management of cancer threats.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096375796250610065705","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The thiazole nucleus serves as a bioactive synthetic scaffold in drug design and discovery due to its diverse pharmacological activities. It was discovered that many types of thiazole derivatives, including those with one, two, or three substitutions, five- or six-membered heterocycles, fused rings, and thiazole-derived Schiff bases, hydrazinyl derivatives, amides, chalcones, and bis-thiazoles, can fight cancer. Thus, the structural diversity of thiazole nuclei makes it one of the significant areas of research in the pharmaceutical field.
Objective: We would like to elaborate on the recent literature available on the antiproliferative property of molecules bearing 1,3-thiazole nuclei.
Methods: This review summarises the anticancer potency of thiazole derivatives collected from recently available scientific literature. We extracted the information from online databases like PubMed, Scopus, and Web of Science using relevant keywords from 2016 to the present. We discuss the current state of thiazole derivatives and highlight the most promising compounds. We also describe how they work and what their half-maximum inhibitory concentration (IC50) is.
Results: Based on our extensive literature review, we found that thiazole derivatives exhibit anticancer activity through their ability to induce apoptosis in cancer cells, mitochondrial membrane disruption by blocking signalling pathways such as Akt, NFkB, PI3K, and Src/Abl, and inhibition of proteins responsible for cell growth. Moreover, thiazole-protein interactions essential for cancer inhibition are predominantly regulated by hydrogen bonding, supported by the sulphur and nitrogen atoms in the thiazole molecule, which effectively interacts with the amino acids serine, tyrosine, and glutamine. π-π stacking and π-cation interactions involving aromatic amino acids such as tryptophan, tyrosine, and phenylalanine, along with hydrophobic effects and van der Waals forces, play a crucial role in thiazole-protein interactions. These interactions dictate binding affinity and efficacy, measured through thermodynamic characteristics such as Binding Constant (Kb), Dissociation Constant (Kd), and Gibbs free energy (ΔG). Comprehending these features is essential for the development of effective thiazole-based anticancer pharmaceuticals.
Conclusion: This cumulative information is enough to give new ideas for the rational drug design of thiazole-based derivatives and could be pursued as a promising lead in the future for the management of cancer threats.
背景:噻唑核由于其多种药理活性,在药物设计和发现中作为生物活性合成支架。人们发现,许多类型的噻唑衍生物,包括具有一个、两个或三个取代、五元或六元杂环、融合环、噻唑衍生的希夫碱、肼基衍生物、酰胺、查尔酮和双噻唑,都可以抗癌。因此,噻唑核结构的多样性使其成为制药领域的重要研究领域之一。目的:对近年来有关含1,3-噻唑核分子的抗增殖性质的文献进行综述。方法:对近年来有关噻唑类化合物的抗癌作用进行综述。我们使用相关关键词从2016年至今的PubMed、Scopus和Web of Science等在线数据库中提取信息。我们讨论了噻唑衍生物的现状,并重点介绍了最有前途的化合物。我们还描述了它们是如何工作的,以及它们的半最大抑制浓度(IC50)是多少。结果:基于我们广泛的文献回顾,我们发现噻唑衍生物通过其诱导癌细胞凋亡的能力,通过阻断Akt、NFkB、PI3K和Src/Abl等信号通路破坏线粒体膜,以及抑制负责细胞生长的蛋白质,显示出抗癌活性。此外,抑制癌症所必需的噻唑-蛋白质相互作用主要由氢键调节,由噻唑分子中的硫和氮原子支持,有效地与氨基酸丝氨酸、酪氨酸和谷氨酰胺相互作用。涉及色氨酸、酪氨酸和苯丙氨酸等芳香氨基酸的π-π堆积和π-阳离子相互作用,以及疏水效应和范德华力,在噻唑-蛋白质相互作用中起着至关重要的作用。通过结合常数(Kb)、解离常数(Kd)和吉布斯自由能(ΔG)等热力学特性测量,这些相互作用决定了结合亲和度和效率。了解这些特征对于开发有效的噻唑类抗癌药物至关重要。结论:这些累积的信息足以为噻唑类衍生物的合理药物设计提供新的思路,并可作为未来癌症威胁管理的有希望的线索。
期刊介绍:
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.